Practice Fusion and Emdeon Team Up to Simplify Medical Claim Filings on Practice Fusion's Electronic Health Record (EHR) Platform

SAN FRANCISCO, June 25, 2014-- Practice Fusion, the country's largest physician-patient community, and Emdeon Inc., a leading provider of healthcare revenue and payment cycle management and clinical information exchange solutions, are teaming up to offer automated health plan eligibility checks in the Practice Fusion EHR.  When scheduling a patient visit through the Practice Fusion EHR, medical professionals will be able to check that patient's health plan information electronically via the Emdeon network, which will eliminate the need to call individual payers to verify coverage.

"With the influx of newly insured patients entering the healthcare system, physicians need a trusted resource that can help manage the complex revenue and payment cycle," said Chris Meffe, senior vice president of the Channel Partner Group for Emdeon. "Working with Practice Fusion will allow Emdeon to reach a large physician community that can benefit from increased visibility relating to patient insurance information."

Emdeon's Intelligent Healthcare NetworkTM connects physicians and other providers to commercial and government health plan payers nationwide. With this integration, medical professionals using the Practice Fusion EHR will have an easy way to verify health plan coverage for patients quickly, which helps to ensure claims will be covered and paid by payers.

"Even though physicians are seeing more patients today than in previous years, many are being forced into bankruptcy or must make the difficult decision to sell their practices," said Ryan Howard, founder and CEO, Practice Fusion. "Physicians are using Practice Fusion to facilitate more than five million patient visits each month.  By adding automated patient eligibility and benefit checks into their existing workflows, we help them get paid and ultimately give them more time to focus on patient care."

For more information on Practice Fusion or to join the more than 112,000 medical professionals that use the Practice Fusion EHR every month, please visit www.practicefusion.com.

About Practice Fusion

Practice Fusion is the largest and fastest-growing healthcare platform, with a mission of connecting doctors, patients and data to drive better health and save lives. A driving force in modernizing American health care, Practice Fusion is used by a community of more than 112,000 monthly active medical professionals with over 81 million patient records. In April 2013, the company launched its consumer-facing platform, Patient Fusion, where patients can find and book appointments with doctors and access their medical records. The World Economic Forum recognized Practice Fusion as a Technology Pioneer for 2013. www.practicefusion.com

About Emdeon

Emdeon is a leading provider of revenue and payment cycle management and clinical information exchange solutions, connecting payers, providers, pharmacies and patients in the U.S. healthcare system. Emdeon's offerings integrate and automate key business and administrative functions of its payer, provider and pharmacy customers throughout the patient encounter. Through the use of Emdeon's comprehensive suite of solutions, which are designed to easily integrate with existing technology infrastructures, customers are able to improve efficiency, reduce costs, increase cash flow and more efficiently manage the complex revenue and payment cycle and clinical information exchange processes. For more information, visit www.emdeon.com.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.